Abstract
Proteins of Bcl-2(B-cell lymphoma-2) family are key regulators of programmed cell death. Scientist found that some members of this family are over-expressed in malignant tumors and influence the sensitivity of tumor cells to chemotherapy and radiotherapy. This report reviews the recent progress of structures, functions and inhibition of Bcl-2 family proteins, especially the development of Bcl-2 inhibitors in past decades as anticancer agents.
Keywords: Apoptosis, Bcl-2, structure, function, inhibitors, anti-tumor
Mini-Reviews in Medicinal Chemistry
Title: Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Volume: 9 Issue: 14
Author(s): Guizhi Xiao, Hao Fang, Chengguo Xing and Wenfang Xu
Affiliation:
Keywords: Apoptosis, Bcl-2, structure, function, inhibitors, anti-tumor
Abstract: Proteins of Bcl-2(B-cell lymphoma-2) family are key regulators of programmed cell death. Scientist found that some members of this family are over-expressed in malignant tumors and influence the sensitivity of tumor cells to chemotherapy and radiotherapy. This report reviews the recent progress of structures, functions and inhibition of Bcl-2 family proteins, especially the development of Bcl-2 inhibitors in past decades as anticancer agents.
Export Options
About this article
Cite this article as:
Xiao Guizhi, Fang Hao, Xing Chengguo and Xu Wenfang, Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents, Mini-Reviews in Medicinal Chemistry 2009; 9 (14) . https://dx.doi.org/10.2174/138955709791012238
DOI https://dx.doi.org/10.2174/138955709791012238 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction by IL-2 and its Receptors as Target in Treatment of Rheumatoid Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Plasmid-Mediated Muscle-Targeted Gene Therapy for Circulating Therapeutic Protein Replacement: A Tale of the Tortoise and the Hare?
Current Gene Therapy Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals Obesity Modulation - The Role in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Current Cancer Therapy Reviews Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects
Current Bioinformatics Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Ectopic Lymphoid Neogenesis and Lymphoid Chemokines in Sjogren’s Syndrome: At the Interplay between Chronic Inflammation, Autoimmunity and Lymphomagenesis
Current Pharmaceutical Biotechnology Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery LncRNAs as Architects in Cancer Biomarkers with Interface of Epitranscriptomics- Incipient Targets in Cancer Therapy
Current Cancer Drug Targets Pomegranate Extracts and Cancer Prevention: Molecular and Cellular Activities
Anti-Cancer Agents in Medicinal Chemistry The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis
Current Pharmaceutical Design The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases
Mini-Reviews in Medicinal Chemistry Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets